Novo outlines obesity growth and DTC strategy under investor pressure

Novo Nordisk presented a new strategy to expand its obesity franchise and pursue direct-to-consumer channels, responding to investor pressure to diversify its pipeline. The plan signals a shift toward consumer-focused distribution and pipeline expansion beyond GLP-1s, though execution risks remain. This matters as Novo's valuation is heavily tied to its obesity portfolio, and any strategic pivot could impact competitive dynamics in the weight-loss drug market.